Table 2.

Risk (hazard ratio and 95% confidence interval) of sudden cardiac death, myocardial infarction, stroke, death due to heart failure, combined cardiovascular events, all-cause mortality, and death due to infection by tertiles of soluble urokinase plasminogen activator receptor at baseline (study population n=1175)

OutcomeHRs Stratified by suPAR Tertiles at Baseline
Tertile 1 ≤9599 pg/ml, n=391Tertile 2 >9599 to ≤11,633 pg/ml, n=392Tertile 3 >11,633 pg/ml, n=392
All-cause mortality
 Crude HR (95% CI)11.51 (1.23 to 1.85)1.90 (1.53 to 2.36)
 Adjusteda HR (95% CI)11.54 (1.24 to 1.92)1.91 (1.51 to 2.40)
 Adjustedb HR (95% CI)11.40 (1.12 to 1.76)1.60 (1.27 to 2.03)
 Adjustedc HR (95% CI)11.37 (1.09 to 1.73)1.51 (1.19 to 1.92)
Cardiovascular eventsd
 Crude HR (95% CI)11.49 (1.17 to 1.90)1.75 (1.38 to 2.20)
 Adjusteda HR (95% CI)11.41 (1.09 to 1.81)1.73 (1.36 to 2.19)
 Adjustedb HR (95% CI)11.30 (1.01 to 1.68)1.48 (1.15 to 1.89)
 Adjustedc HR (95% CI)11.29 (1.00 to 1.67)1.45 (1.13 to 1.88)
Sudden cardiac death
 Crude HR (95% CI)11.90 (1.21 to 3.00)2.31 (1.51 to 3.53)
 Adjusteda HR (95% CI)11.81 (1.13 to 2.91)2.27 (1.45 to 3.55)
 Adjustedb HR (95% CI)11.62 (1.01 to 2.61)1.98 (1.27 to 3.09)
 Adjustedc HR (95% CI)11.62 (1.01 to 2.61)1.95 (1.22 to 3.10)
Myocardial infarction
 Crude HR (95% CI)11.76 (0.94 to 3.32)0.84 (0.36 to 1.96)
 Adjusteda HR (95% CI)12.03 (1.06 to 3.87)0.89 (0.39 to 2.04)
 Adjustedb HR (95% CI)11.91 (0.98 to 3.72)0.80 (0.34 to 1.90)
 Adjustedc HR (95% CI)11.84 (0.93 to 3.63)0.76 (0.31 to 1.88)
Stroke
 Crude HR (95% CI)11.55 (0.90 to 2.65)2.41 (1.46 to 3.98)
 Adjusteda HR (95% CI)11.41 (0.81 to 2.44)2.30 (1.39 to 3.78)
 Adjustedb HR (95% CI)11.27 (0.74 to 2.17)1.74 (1.05 to 2.90)
 Adjustedc HR (95% CI)11.26 (0.73 to 2.18)1.74 (1.02 to 2.98)
Death due to heart failure
 Crude HR (95% CI)10.98 (0.42 to 2.28)2.40 (1.11 to 5.20)
 Adjusteda HR (95% CI)11.12 (0.45 to 2.82)2.64 (1.15 to 6.03)
 Adjustedb HR (95% CI)11.09 (0.43 to 2.77)2.42 (1.02 to 5.71)
 Adjustedc HR (95% CI)11.05 (0.41 to 2.69)2.08 (0.88 to 4.91)
Death due to infection
 Crude HR (95% CI)11.21 (0.77 to 1.85)1.40 (1.02 to 2.18)
 Adjusteda HR (95% CI)11.24 (0.76 to 2.04)1.44 (0.93 to 2.22)
 Adjustedb HR (95% CI)11.09 (0.67 to 1.78)1.03 (0.66 to 1.59)
 Adjustedc HR (95% CI)11.07 (0.65 to 1.76)0.96 (0.62 to 1.50)
  • HR, hazard ratio; suPAR, soluble urokinase plasminogen activator receptor; 95% CI, 95% confidence interval.

  • a Adjusted HR: adjustments were made for age, sex, body mass index, hypertension, LDL, HDL cholesterol, and antiplatelet and angiotensin-converting enzyme inhibitor therapy.

  • b Adjusted HR: adjustments were made for age, sex, body mass index, hypertension, LDL, HDL cholesterol, antiplatelet and angiotensin-converting enzyme inhibitor therapy, heart failure, coronary artery disease, peripheral vascular disease, diuretics, vascular access, hemoglobin, albumin, and phosphate.

  • c Adjusted HR: adjustments were made for age, sex, body mass index, hypertension, LDL, HDL cholesterol, antiplatelet and angiotensin-converting enzyme inhibitor therapy, heart failure, coronary artery disease, peripheral vascular disease, diuretics, vascular access, hemoglobin, albumin, phosphate, C-reactive protein, leukocyte count, and asymmetric dimethyl arginine.

  • d Combined cardiovascular events were defined as a composite of death from cardiac causes, fatal or nonfatal stroke, and nonfatal myocardial infarction, whichever occurred first. Death from cardiac causes comprised sudden cardiac death, fatal myocardial infarction, death due to congestive heart failure, death due to coronary heart disease during or within 28 days after an intervention, and all other deaths attributable to coronary heart disease.